Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Panax notoginseng, commonly known as Sanqi or Notoginseng, is a perennial herb in the Araliaceae family and a cornerstone of Traditional Chinese Medicine (TCM). Sun Ten Laboratories provides this botanical as a concentrated herbal extract, typically in a 5:1 ratio, for use in clinical TCM practice. The herb is traditionally classified as a hemostatic agent that also possesses the unique ability to 'invigorate blood,' meaning it can stop bleeding without causing blood stasis. Its primary active constituents are dammarane-type triterpene saponins, specifically notoginsenosides (such as Notoginsenoside R1) and ginsenosides (such as Rb1, Rg1, and Rd). These compounds are studied for their multi-target effects on the cardiovascular system, including the inhibition of platelet aggregation, reduction of inflammatory cytokines, and protection of vascular endothelial cells. Sun Ten markets this product as a dietary supplement and herbal ingredient rather than a regulated pharmaceutical drug.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Panax notoginseng (Sun Ten).